Markets:

Overview

News

Currencies

International

Treasuries

Centessa Pharmaceuticals plc - American Depositary Shares (NQ:CNTA)

23.95 +0.42 (+1.78%)

Streaming Delayed Price Updated: 10:48 AM EST, Feb 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Centessa Pharmaceuticals plc - American Depositary Shares

< Previous 1 2 3 4 5 6 7 Next >

Bronstein, Gewirtz & Grossman, LLC, A Top Firm, Notifies Centessa Pharmaceuticals plc (CNTA) Investors of Class Action and Encourages Investors to Actively Participate

October 13, 2022

From Bronstein, Gewirtz & Grossman, LLC

Via Business Wire

NASDAQ:CNTA Shareholder Notice: Lawsuit Alleges Securities Laws Violations by Centessa Pharmaceuticals Plc ↗

October 12, 2022

San Diego, CA -- (SBWIRE) -- 10/12/2022 -- An investor, who purchased shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA), filed a lawsuit against Centessa Pharmaceuticals plc over alleged Federal...

Via SBWire

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Centessa, PayPal, Opendoor, and Schmitt and Encourages Investors to Contact the Firm

October 11, 2022

From Bragar Eagel & Squire

Via GlobeNewswire

Analyst Ratings for Centessa Pharmaceuticals ↗

August 11, 2022

Within the last quarter, Centessa Pharmaceuticals (NASDAQ:CNTA) has observed the following analyst ratings:

Via Benzinga

Centessa Culls Early-Stage Asset For Inherited Disorder ↗

August 10, 2022

Via Benzinga

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Centessa and PayPal and Encourages Investors to Contact the Firm

October 06, 2022

From Bragar Eagel & Squire

Via GlobeNewswire

Centessa Pharmaceuticals Plc (NASDAQ:CNTA) Investor Alert: Investigation over Potential Wrongdoing ↗

October 05, 2022

San Diego, CA -- (SBWIRE) -- 10/05/2022 -- An investigation on behalf of investors in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) was announced over potential breaches of fiduciary duties by...

Via SBWire

INVESTOR NOTICE: Centessa Pharmaceuticals plc Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – CNTA

October 03, 2022

From Robbins Geller Rudman & Dowd LLP

Via Business Wire

BMO Capital Sees Almost 300% Upside On Centessa Stock ↗

June 17, 2022

Via Benzinga

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Olo and Centessa and Encourages Investors to Contact the Firm

October 02, 2022

From Bragar Eagel & Squire

Via GlobeNewswire

CENTESSA PHARMACEUTICALS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Centessa Pharmaceuticals plc - CNTA

September 30, 2022

From Kahn Swick & Foti, LLC

Via Business Wire

Centessa Pharmaceuticals plc Shareholder Update: Robbins LLP Reminds Investors of Class Action Against Centessa Pharmaceuticals plc (CNTA)

September 30, 2022

From Robbins LLP

Via Business Wire

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Centessa Pharmaceuticals plc with Losses of $100,000 to Contact the Firm

September 30, 2022

From The Schall Law Firm

Via Business Wire

CENTESSA ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Centessa Pharmaceuticals Plc and Encourages Investors to Contact the Firm

September 29, 2022

From Bragar Eagel & Squire, P.C.

Via Business Wire

INVESTOR ALERT: Centessa Pharmaceuticals plc Investors with Substantial Losses Have Opportunity to Lead the Centessa Class Action Lawsuit - CNTA

September 29, 2022

From Robbins Geller Rudman & Dowd LLP

Via Business Wire

Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Centessa Pharmaceuticals plc (CNTA)

September 29, 2022

From Robbins LLP

Via Business Wire

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Centessa Pharmaceuticals plc with Losses of $100,000 to Contact the Firm

September 29, 2022

From The Schall Law Firm

Via Business Wire

Important Biotech Catalysts For September 14, 2022 - End Of The Day Summary ↗

September 14, 2022

Via Benzinga

FDA Grants Orphan Drug Status To Centessa's Hemophilia B Candidate ↗

September 14, 2022

Centessa Pharmaceuticals (NASDAQ: CNTA) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to SerpinPC for the treatment of hemophilia B. A Phase 2a...

Via Benzinga

Centessa Pharmaceuticals Plc (NASDAQ:CNTA) Shareholder Notice: Investigation over Potential Securities Laws Violations ↗

August 23, 2022

San Diego, CA -- (SBWIRE) -- 08/23/2022 -- Centessa Pharmaceuticals plc is under investigation concerning possible securities laws violations in connection with certain financial statements.

Via SBWire

INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Centessa Pharmaceuticals plc with Losses of $100,000 to Contact the Firm

August 15, 2022

From The Schall Law Firm

Via Business Wire

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Centessa Pharmaceuticals plc with Losses of $100,000 to Contact the Firm

August 12, 2022

From The Schall Law Firm

Via Business Wire

Morgan Stanley Downgrades Centessa Pharmaceuticals: Here's What You Need To Know ↗

August 12, 2022

Morgan Stanley downgraded its rating of Centessa Pharmaceuticals (NASDAQ:CNTA) to Underweight with a price target of $5.00, changing its price target from $10.00 to $5.00. Shares of Centessa...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 12, 2022 ↗

August 12, 2022

Via Benzinga

EQUITY ALERT: Rosen Law Firm Encourages Centessa Pharmaceuticals plc Investors with Losses in Excess of $100K to Inquire About Class Action Investigation – CNTA

August 12, 2022

From The Rosen Law Firm, P.A.

Via Business Wire

Goldman Sachs Maintains Neutral Rating for Centessa Pharmaceuticals: Here's What You Need To Know ↗

August 11, 2022

Goldman Sachs has decided to maintain its Neutral rating of Centessa Pharmaceuticals (NASDAQ:CNTA) and lower its price target from $5.00 to $4.00. Shares of Centessa Pharmaceuticals are trading down...

Via Benzinga

Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial ↗

August 10, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Centessa Pharmaceuticals: Q2 Earnings Insights ↗

August 10, 2022

Centessa Pharmaceuticals (NASDAQ:CNTA) reported its Q2 earnings results on Wednesday, August 10, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

89 Biggest Movers From Friday ↗

June 21, 2022

Gainers Revlon, Inc. (NYSE: REV) jumped 91.3% to close at $3.73 on Friday after the company filed for Chapter 11 bankruptcy.

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

June 03, 2022

During Friday's trading, 69 companies set new 52-week lows.

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.